In Patients with Endometrial Cancer, Radiation Therapy with Concurrent Paclitaxel After Surgery is Effective
the Cancer Therapy Advisor take:
According to a study published in the International Journal of Radiation Oncology, Biology, and Physics, researchers found that radiotherapy in combination with paclitaxel is effective for the treatment of patients with high-risk endometrial cancer following surgery.
In the phase 2 study, researchers enrolled 57 patients from 2006 to 2008 with stage 3 or 4 treatment-naive endometrioid adenocarcinoma. Researchers initiated the combination therapy 6 weeks after surgery with radiation therapy starting either 2 days before or after the first paclitaxel treatment.
At the 5-year follow-up, patients had an average disease-free survival rate of 63.5% (95% CI) and an overall survival rate of 82.7% (95% CI). Researchers also observed diseased recurrence in 36.5% of patients and 17.3% had died due to endometrial cancer. Common adverse effects were leukopenia and neutropenia, as expected with paclitaxel therapy. Chemotherapy was only discontinued in two patients due to adverse effects.
Researchers suggest that this study demonstrates that patients with advanced endometrial cancer should be treated with chemotherapy and radiation therapy, but further larger studies should be conducted to prove this treatment approach.
Radiotherapy in combination with paclitaxel effective for the treatment of endometrial cancer.
Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the September 1, 2014 edition of the International Journal of Radiation Oncology, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Endometrial cancer is the most common gynecologic malignancy. Patients with early-stage disease are typically treated with surgery alone; however, patients with advanced endometrial cancer have higher instances of local or distant recurrence.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer